TOKYO (Kyodo) -- Takeda Pharmaceutical Co., Japan's biggest drug maker, said Tuesday that its vaccine for dengue fever had been approved in Indonesia, apparently making it the first Japanese company to sell a vaccine abroad.
The medical group, which has lagged behind in COVID-19 vaccine development, said it is also applying for approval of its inoculation against dengue fever in Asian and South American countries as well as in the European Union, aiming to push its annual sales up to $1.6 billion.
